Search | Clinical Trials Finder

Conditions: Drug Toxicity
Interventions: HPN-100, HPN-100 or Placebo, Placebo, Moxifloxacin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Huntington Disease
Interventions: Dimebon, Placebo; Drug · Other
Lead sponsor: Medivation, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 24
States / cities: Scottsdale, Arizona • Davis, California • Irvine, California + 21 more

Conditions: Congenital Myasthenic Syndrome, CMS
Interventions: ARGX-119, Placebo; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Sacramento, California • Chicago, Illinois

Conditions: AL Amyloidosis
Interventions: NEOD001, Placebo; Drug
Lead sponsor: Prothena Biosciences Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 19
States / cities: Duarte, California • Stanford, California • Denver, Colorado + 15 more

Conditions: Parkinson's Disease
Interventions: Prasinezumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 53
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo matched to atacicept, Atacicept: with loading dose, Atacicept, Adalimumab; Drug · Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Oral Mucositis, Head and Neck Cancer
Interventions: EN3285, Placebo, Standard of care; Drug · Other
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Louisville, Kentucky • Houston, Texas

Conditions: Influenza -Like Illness
Interventions: Norketotifen, Placebo; Drug
Lead sponsor: Emergo Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 14 more

Conditions: Asthma
Interventions: Placebo, Benralizumab; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 9
States / cities: Tampa, Florida • Springfield, Massachusetts • Detroit, Michigan + 6 more

Conditions: Treatment Resistant Depression, Treatment Resistant Depression (TRD)
Interventions: Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS, Oral Placebo; Device · Drug
Lead sponsor: NeuroRx, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Sarasota, Florida • West Palm Beach, Florida • Belmont, Massachusetts

Conditions: Pain, Postoperative, Delirium, Anesthesia, Local
Interventions: Ropivacaine HCL, sodium chloride; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Amyotrophic Lateral Sclerosis
Interventions: DNL343, Matching Placebo; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years to 100 Years
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ulcerative Colitis
Interventions: OPC-6535 Tablets (drug); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 28
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 25 more

Conditions: Surgical Procedures
Interventions: GSK1278863, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 10 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 80
States / cities: Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more

Conditions: Metabolic Disorders, Non-alcoholic Steatohepatitis
Interventions: AZD2693, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Dental Caries
Interventions: Resin infiltration, Sham treatment; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 24 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: West Point, New York

Conditions: Autism Spectrum Disorder
Interventions: Suramin Sodium; Drug
Lead sponsor: Paxmedica; Industry
Eligibility: 4 Years to 17 Years · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: IUD Insertion
Interventions: Vaginal 2% Lidocaine, Surgical Lubricant Jelly; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Myositis, Interstitial Lung Disease
Interventions: Abatacept, Placebo; Drug · Other
Lead sponsor: Rohit Aggarwal, MD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 5
States / cities: Beverly Hills, California • Denver, Colorado • Baltimore, Maryland + 2 more

Conditions: Sjogrens Disease
Interventions: Abatacept, Placebo; Biological · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 19
States / cities: Fullerton, California • Riverside, California • Lakewood, Colorado + 14 more

Conditions: Rapid Atrial Fibrillation, Heart Rate Control
Interventions: Dexmedetomidine Hydrochloride, Normal Saline; Drug · Other
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Familial Chylomicronemia Syndrome (FCS)
Interventions: LCQ908, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Seatlle, Washington

Conditions: Flushing, Alcohol-Related Disorders, Aldehyde Dehydrogenase Deficiency
Interventions: Brimonidine Tartrate, Placebo Vehicle Gel; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer

Norketotifen for the Treatment of Uncomplicated Influenza-like Illness

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

Study to Determine if Pre- and Post- Operative TAP Catheters With Ropivacaine Versus Placebo Affects Anesthetic, Narcotic Dosing, and Pain Scores

HEALEY ALS Platform Trial - Regimen G DNL343

FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

Resin Infiltration to Arrest Early Tooth Decay

Double Blind Trial in Children With Autism Spectrum Disorder

Self-Administered Lidocaine Gel for Pain Management With IUD Insertion

Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease

A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome

Controlling Rapid Atrial Fibrillation With Dexmedetomidine

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists